The Zacks Consensus Estimate for current-year earnings has improved by 15.8% over the past 30 days. The stock's last closing price is $4.99. Aduro Biotech, Inc. is a development-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for challenging diseases. Aduro Biotech has a Zacks Rank #2. The company has expected earnings growth of 34.7% for the current year. The Zacks Consensus Estimate for current-year earnings has improved by 32.2% over the past 30 days. The stock's last closing price is $3.50.